Rinvoq is classified as a Janus kinase (JAK) inhibitor [1]. It specifically targets and inhibits JAK1 [2].
How do JAK inhibitors work?
Janus kinases are enzymes involved in signaling pathways that regulate immune responses and inflammation [1]. By inhibiting JAK1, Rinvoq blocks these signaling pathways, which helps to reduce inflammation in conditions like rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis [2][3].
What conditions is Rinvoq approved to treat?
Rinvoq is approved for the treatment of adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderate to severe atopic dermatitis [2][3][4]. It is also indicated for adults with moderately to severely active ulcerative colitis and Crohn's disease [4].
When does Rinvoq's patent expire?
Patent expiry dates can vary and are subject to challenges. Information on specific patent expirations for Rinvoq can be found on resources like DrugPatentWatch.com [5]. For example, patents related to the drug substance and its uses are typically filed, with varying expiration timelines.
Are there other drugs in the same class as Rinvoq?
Yes, other JAK inhibitors are available, though they may differ in their specific JAK enzyme targets and approved indications. Examples include tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq), all of which target JAK enzymes to modulate immune responses [1][2][3].
What are the risks associated with JAK inhibitors like Rinvoq?
Like other JAK inhibitors, Rinvoq carries boxed warnings for serious infections, mortality, major cardiovascular events, and thrombosis [2][4]. Patients should discuss potential risks and benefits with their healthcare provider.
What is the difference between Rinvoq and other treatments for inflammatory conditions?
Rinvoq, as a JAK inhibitor, works by targeting intracellular signaling pathways. This differs from other treatment classes for inflammatory conditions, such as biologics (e.g., TNF inhibitors) which target specific proteins outside the cell, or conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) [1][3].
Can biosimilars be developed for Rinvoq?
The development of biosimilars for JAK inhibitors like Rinvoq is contingent upon patent expiry and regulatory pathways. Biosimilar development aims to create highly similar versions of biologic medicines, but the process for small molecule drugs like Rinvoq is different from that for complex biologics.
Who manufactures Rinvoq?
Rinvoq is manufactured by AbbVie [2][3][4].
---
1. "Janus Kinase (JAK) Inhibitors." National Rheumatoid Arthritis Society, https://www.nras.org.uk/types-of-treatment/medications/janus-kinase-jak-inhibitors
2. "Rinvoq." U.S. Food and Drug Administration, https://www.fda.gov/drugs/drug-approvals/rinvoq-upadacitinib
3. "Rinvoq." European Medicines Agency, https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq
4. "Rinvoq Prescribing Information." AbbVie, https://www.rxabbvie.com/pdf/rinvoq_pi.pdf
5. DrugPatentWatch.com, https://drugpatentwatch.com/